Table 2 The compounds targeting lipid metabolism in PC therapy
From: Targeting lipid metabolism: novel insights and therapeutic advances in pancreatic cancer treatment
Compound | Remark | Ref |
|---|---|---|
(-)-epigallocatechin-3-gallate (EGCG) | The suppression of the β-ketoacyl-ACP synthase domain of FASN to impair pancreatic cancer progression | [153] |
Orlistat | FASN downregulation impairs proliferation and induces apoptosis | [89] |
Proton pump inhibitors (lansoprazole, rabeprazole, omeprazole, and pantoprazole) | Inhibition of thioesterase activity to impair cancer progression | [154] |
SCD inhibitor, A939572 | Stearoyl-CoA Desaturase downregulation to mediate unfolded protein response in impairing cancer growth | [155] |
Avasimibe encapsulated in human serum albumin | Suppressing cholesterol esterification | [156] |